214 related articles for article (PubMed ID: 24914616)
1. Nanomechanical property maps of breast cancer cells as determined by multiharmonic atomic force microscopy reveal Syk-dependent changes in microtubule stability mediated by MAP1B.
Krisenko MO; Cartagena A; Raman A; Geahlen RL
Biochemistry; 2015 Jan; 54(1):60-8. PubMed ID: 24914616
[TBL] [Abstract][Full Text] [Related]
2. Fast, multi-frequency, and quantitative nanomechanical mapping of live cells using the atomic force microscope.
Cartagena-Rivera AX; Wang WH; Geahlen RL; Raman A
Sci Rep; 2015 Jun; 5():11692. PubMed ID: 26118423
[TBL] [Abstract][Full Text] [Related]
3. Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase.
Li J; Sidell N
Int J Cancer; 2005 Oct; 117(1):14-20. PubMed ID: 15880583
[TBL] [Abstract][Full Text] [Related]
4. Regulation of microtubule formation in activated mast cells by complexes of gamma-tubulin with Fyn and Syk kinases.
Sulimenko V; Dráberová E; Sulimenko T; Macurek L; Richterová V; Dráber P; Dráber P
J Immunol; 2006 Jun; 176(12):7243-53. PubMed ID: 16751367
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis.
Chakraborty G; Rangaswami H; Jain S; Kundu GC
J Biol Chem; 2006 Apr; 281(16):11322-31. PubMed ID: 16474166
[TBL] [Abstract][Full Text] [Related]
6. [Regulatory role of Syk gene on vascular endothelial growth factor C expression in breast cancer].
Chen XL; Li L; Zhang YJ
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):805-9. PubMed ID: 22336204
[TBL] [Abstract][Full Text] [Related]
7. Modulation by Syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells.
Fei B; Yu S; Geahlen RL
Biochim Biophys Acta; 2013 Oct; 1833(10):2153-64. PubMed ID: 23684705
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.
Xia TS; Shi JP; Ding Q; Liu XA; Zhao Y; Liu YX; Xia JG; Wang S; Ding YB
Med Oncol; 2012 Jun; 29(2):448-53. PubMed ID: 21347717
[TBL] [Abstract][Full Text] [Related]
9. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival.
Dejmek J; Leandersson K; Manjer J; Bjartell A; Emdin SO; Vogel WF; Landberg G; Andersson T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):520-8. PubMed ID: 15701836
[TBL] [Abstract][Full Text] [Related]
10. [Functions of spleen tyrosine kinase (Syk) gene and its correlation to neoplasms].
Wang HY; Zhang ZX
Ai Zheng; 2007 May; 26(5):555-60. PubMed ID: 17672952
[TBL] [Abstract][Full Text] [Related]
11. Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells.
Zhang X; Shrikhande U; Alicie BM; Zhou Q; Geahlen RL
Mol Cancer Res; 2009 May; 7(5):634-44. PubMed ID: 19435818
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract][Full Text] [Related]
13. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Mahabeleshwar GH; Kundu GC
J Biol Chem; 2003 Feb; 278(8):6209-21. PubMed ID: 12477728
[TBL] [Abstract][Full Text] [Related]
14. Syk inhibits the activity of protein kinase A by phosphorylating tyrosine 330 of the catalytic subunit.
Yu S; Huang H; Iliuk A; Wang WH; Jayasundera KB; Tao WA; Post CB; Geahlen RL
J Biol Chem; 2013 Apr; 288(15):10870-81. PubMed ID: 23447535
[TBL] [Abstract][Full Text] [Related]
15. Identification of BCAR-1 as a new substrate of Syk tyrosine kinase through a determination of amino acid sequence preferences surrounding the substrate tyrosine residue.
Kim JY; Huh K; Jung R; Kim TJ
Immunol Lett; 2011 Mar; 135(1-2):151-7. PubMed ID: 21047529
[TBL] [Abstract][Full Text] [Related]
16. The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy.
Navara CS
Curr Pharm Des; 2004; 10(15):1739-44. PubMed ID: 15180536
[TBL] [Abstract][Full Text] [Related]
17. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck.
Luangdilok S; Box C; Patterson L; Court W; Harrington K; Pitkin L; Rhŷs-Evans P; O-charoenrat P; Eccles S
Cancer Res; 2007 Aug; 67(16):7907-16. PubMed ID: 17699797
[TBL] [Abstract][Full Text] [Related]
18. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells.
Lu J; Lin WH; Chen SY; Longnecker R; Tsai SC; Chen CL; Tsai CH
J Biol Chem; 2006 Mar; 281(13):8806-14. PubMed ID: 16431925
[TBL] [Abstract][Full Text] [Related]
19. The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells.
Zhou Q; Geahlen RL
Oncogene; 2009 Mar; 28(10):1348-56. PubMed ID: 19151749
[TBL] [Abstract][Full Text] [Related]
20. The lymphoma-associated fusion tyrosine kinase ITK-SYK requires pleckstrin homology domain-mediated membrane localization for activation and cellular transformation.
Rigby S; Huang Y; Streubel B; Chott A; Du MQ; Turner SD; Bacon CM
J Biol Chem; 2009 Sep; 284(39):26871-81. PubMed ID: 19535334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
